Cytek Biosciences, Inc.
CTKBUS売上高
$201M
百万USD
営業利益
$-40M
百万USD
純利益
$-67M
百万USD
ROE
-19.5%
最新FY
EPS
-
USD / 株
配当
-
USD / 株
業績推移
収益性
キャッシュフロー
財務状況
四半期業績
| 年度 | 期 | 売上高 | 純利益 | EPS |
|---|---|---|---|---|
| FY2021 | Q2 | $30M | $3M | $0.06 |
| FY2021 | Q3 | $34M | $1M | $0.00 |
| FY2021 | FY | $128M | $3M | $0.00 |
| FY2022 | Q1 | $35M | $-2M | $0.02 |
| FY2022 | Q2 | $40M | $-1M | $0.00 |
| FY2022 | Q3 | $40M | $2M | $-0.01 |
| FY2022 | FY | $164M | $2M | $0.02 |
| FY2023 | Q1 | $37M | $-7M | - |
| FY2023 | Q2 | $50M | $-4M | - |
| FY2023 | Q3 | $48M | - | - |
| FY2023 | FY | $193M | $-12M | $-0.09 |
| FY2024 | Q1 | $45M | - | - |
| FY2024 | Q2 | $47M | - | - |
| FY2024 | Q3 | $52M | - | - |
| FY2024 | FY | $200M | $-6M | - |
| FY2025 | Q1 | $41M | $-11M | - |
| FY2025 | Q2 | $46M | - | - |
| FY2025 | Q3 | $52M | - | - |
| FY2025 | FY | $201M | $-67M | - |
| FY2026 | Q1 | $44M | $-19M | - |
財務データ
| 指標 | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
| 売上高 | $128M | $164M | $193M | $200M | $201M |
| 営業利益 | $9M | $-2M | $-28M | $-21M | $-40M |
| 純利益 | $3M | $2M | $-12M | $-6M | $-67M |
| 総資産 | $463M | $519M | $494M | $500M | $462M |
| 純資産 | - | - | - | - | $342M |
| 自己資本 | $405M | $426M | $393M | $396M | $342M |
| 営業CF | $5M | $-12M | $5M | $25M | $-5M |
| EPS | $0.00 | $0.02 | $-0.09 | - | - |
| BPS | $3.02 | $3.14 | $3.00 | $3.09 | $2.66 |
| ROE | 0.7% | 0.6% | -3.1% | -1.5% | -19.5% |